Table 1

Subjects’ demographics and clinical characteristics (N = 582)

Age, years, mean (SD)9.98 (3.82)
 4–8, years, n (%)224 (38.49)
 9–18, years, n (%)358 (61.51)
Sex, n (%)
 Female232 (39.86)
 Male350 (60.14)
Race, n (%)
 White529 (92.71)
 Nonwhite41 (5.23)
 Unknown12 (2.06)
Relationship to proband, n (%)
 Sibling367 (63.06)
 Offspring156 (26.80)
 Parent1 (0.17)
 Non–first degree relative58 (9.97)
BMIZ percentile and age, mean (SD)57.80 (29.38)
 <85.0, n (%)416 (71.48)
 ≥85.0, n (%)132 (22.68)
 Unknown34 (5.84)
HLA risk, n (%)
 High risk492 (84.54)
 Low risk88 (15.12)
 Unknown2 (0.34)
Number of positive antibodies, n (%)
 133 (5.67)
 255 (9.45)
 3205 (35.22)
 4289 (49.66)
ICA titer, median (Q1–Q3)160.00 (40.00–320.00)
IAA titer, median (Q1–Q3)185.90 (69.20–450.30)
GAD65A titer, median (Q1–Q3)0.260 (0.049–0.744)
ICA512A titer, median (Q1–Q3)0.105 (0.013–0.714)
  • Q1, the first quantile; Q3, the third quantile.